Sanofi (SNY) Market Capitalization, Earnings, Price, Holders
Symbol: SNY Rank: #87 Price: $54.3831(0.30081%)

Market Cap: $138.1B($415.6M) Industry: Drug Manufacturers General Sector: Healthcare Country: France Insiders: 0.006% Institutions: 10.457%
Sanofi Technicals

52 Week High: $55.28

52 Week Low: $36.38

50 Day MA: $47.4

200 Day MA: $45.69

52 Week Trading Range


Low: $36.38

High: $55.28

Daily Trading Range


Low: $54.35

High: $54.79

Market capitalization history for Sanofi (SNY) in USD

As of November 2023, Sanofi (SNY) has a market cap of $138.1 billion. Our data points out that SNY is ranked #87 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. SNY's market cap is 0.300807% up from the last trading day.

SNY Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (SNY)

Latest News

Sanofi (SNY) Shares Stats
Sanofi (SNY) Valuation
Trailing P/E $13.24
Forward P/E $10.34
Price Sales TTM $2.65
Price Book MRQ $1.6
Enterprise Value $133,436,754,920
Enterprise Value Revenue $3.01
Enterprise Value Ebitda $13.38
Sanofi Details

Address: 54, Rue La BoEtie

City: Paris

Zip: 75008

Phone: 33 1 53 77 40 00


IPO Date: 2002-07-01

CEO: Paul Hudson

Employees: 95,442

What is SNY about?

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.